Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02269111 · ClinicalTrials.gov registry record · NA
Quantitative MRI in Assessing Disease in Patients With Brain Tumors
A NA study, sponsored by Vanderbilt-Ingram Cancer Center.
- Terminated
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT02269111: Clinical Trial NA study, sponsored by Vanderbilt-Ingram Cancer Center.
NCT02269111 is a NA study that was terminated before completion, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 10 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02269111, a NA study, was terminated before completion, sponsored by Vanderbilt-Ingram Cancer Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
This pilot clinical trial studies quantitative magnetic resonance imaging (MRI) at 3 Tesla in assessing disease in patients with tumors that have spread to the brain (brain metastases). In addition to routine care brain imaging of the brain, this study will include advanced multiparametric MRI sequences to measure vascular, cellular, and molecular properties of the tumor. Performing extra scans during MRI provides more information about the metastases and may better predict treatment response.
Primary Outcome
The ability of pre-treatment estimates of Ktrans to predict objective tumor response by Response Evaluation Criteria in Solid Tumors or Macdonald criteria after therapy will be assessed using the proportional odds model.
Interventions
- PROCEDURE diffusion-weighted magnetic resonance imaging
- PROCEDURE dynamic contrast-enhanced magnetic resonance imaging
- PROCEDURE chemical exchange saturation transfer magnetic resonance imaging
- PROCEDURE dynamic susceptibility contrast-enhanced magnetic resonance imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2015-04 |
| Est. Completion | 2018-05 |
| Phase | NA |
Why NCT02269111 stopped before completion
NCT02269111 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 4 interventions - of which diffusion-weighted magnetic resonance imaging is the first listed.
NCT02269111 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02269111 about?
NCT02269111 is a clinical study titled "Quantitative MRI in Assessing Disease in Patients With Brain Tumors". This pilot clinical trial studies quantitative magnetic resonance imaging (MRI) at 3 Tesla in assessing disease in patients with tumors that have spread to the brain (brain metastases). In addition to routine care brain imaging of the brain, this study will include advanced multiparametric MRI seque...
What is the current status of trial NCT02269111?
This trial is currently terminated. It is a NA study. The enrollment target is 10 participants. The study started on 2015-04. Estimated completion is 2018-05.
What interventions are being tested in trial NCT02269111?
The interventions under investigation include: diffusion-weighted magnetic resonance imaging (PROCEDURE), dynamic contrast-enhanced magnetic resonance imaging (PROCEDURE), chemical exchange saturation transfer magnetic resonance imaging (PROCEDURE), dynamic susceptibility contrast-enhanced magnetic resonance imaging (PROCEDURE).
Who is sponsoring clinical trial NCT02269111?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02269111's enrollment target sits among peer trials
10 1927th of 2000 higher than 26 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia